Abstract: . . .  Page 9 Angina Pectoris : Management Strategies Graboys & Blatt Professional Communications, Inc. Page 117 230 231 Lotensin (benazepril), dosage and pharmacokinetics of, 118t Lunch, dietary recommendations for, 132 Lung:heart thallium uptake ratio. See also Perfusion imaging . as indication for CABG surgery, 167 as indication for coronary angiography, 154-155 Lungs congestion in, 42 pain in, 48 M (motion) mode, of echocardiography, 59 Male gender, as nonmodifiable risk factor, 16 . . .
. . .  echocardiography of, 60-61, 63 normalcy of, in angina , 61 Ventricular impulse, displaced, 42 Ventricular tachycardia as indication for coronary angioplasty, 154 ST-segment depression with, 51-52 Page 14 Angina Pectoris : Management Strategies Graboys & Blatt Professional Communications, Inc. Page 122 240 Ventriculography, using radionuclide indications for, 63 parameters of, 62 Verapamil (Isoptin, Verelan) adverse effects of, 104 for atrial fibrillation, 178 -blocker . . .
. . .  186t Alprazolam (Xanax), dosage, pharmacokinetics, and side effects of, 121t Altace (ramipril), dosage and pharmacokinetics of, 118t Ambulatory electrocardiographic monitoring advantages of, 65 of autonomic tone, 68 false positive results of, 67 of heart rate variability, 68 history of, 65 indications for, 65-66, 153 of silent ischemia, 65, 67 technique of, 66-67 American Heart Association/American College of Cardiology Guidelines and Indications for Coronary Artery Bypass Surgery, 166 Amlodipine (Norvasc) adverse . . .
. . .  electrocardiographic monitoring of, 66 early onset of, 52 during exercise, 50, 129, 201-202, 204 interpretation of, in ambulatory electrocardiographic monitoring, 67 prognosis of, 52 in silent ischemia, 66 ventricular tachycardia with, 51-52, 55 ST-T wave, diffuse changes in, 48 Stable angina , captopril for, 116 Stair climbing, provocation by, 40, 206 Stenting, 162 re-occlusion after, 168 Stress -blockers and, 87 coronary vasospasm and, 26-27 EDRF release during, 81 management of, 21, 74, 145-147 myocardial oxygen . . .
. . .  Women affective disorders in, 193 aspirin effectiveness in, 193-195 cardiac mortality in, 191, 195 chest pain in, 191-192, 204 coexisting disorders in, 191, 195, 205 drug metabolism in, 193 exercise treadmill testing in, 192-193, 195 invasive management of angina in, 193-195 Xanax (alprazolam), dosage, pharmacokinetics, and side effects of, 121t Xanthelasma, 41 Zestril (lisinopril), dosage and pharmacokinetics of, 118t  . . .
--3000,5,300,3261,48498